A
1.66
-0.04 (-2.35%)
| Previous Close | 1.70 |
| Open | 1.74 |
| Volume | 1,439,123 |
| Avg. Volume (3M) | 511,898 |
| Market Cap | 32,347,144 |
| Price / Book | 2.37 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Diluted EPS (TTM) | -2.24 |
| Current Ratio (MRQ) | 10.68 |
| Operating Cash Flow (TTM) | -22.96 M |
| Levered Free Cash Flow (TTM) | -13.95 M |
| Return on Assets (TTM) | -91.05% |
| Return on Equity (TTM) | -280.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Annovis Bio, Inc. | Bearish | Bearish |
AIStockmoo Score
1.0
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 3.0 |
| Average | 1.00 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.69% |
| % Held by Institutions | 16.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Greenwich Wealth Management Llc | 30 Jun 2025 | 47,000 |
| Wescott Financial Advisory Group, Llc | 30 Jun 2025 | 41,607 |
| Lokken Investment Group Llc | 30 Jun 2025 | 29,235 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 17.00 (Canaccord Genuity, 924.10%) | Buy |
| Median | 13.50 (713.25%) | |
| Low | 10.00 (HC Wainwright & Co., 502.41%) | Buy |
| Average | 13.50 (713.25%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.18 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 30 Sep 2025 | 17.00 (924.10%) | Buy | 2.07 |
| HC Wainwright & Co. | 03 Sep 2025 | 10.00 (502.41%) | Buy | 2.28 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |